Member Info for Muminr

No John Henry, LinkedIn says Patrik Breen is in a different role. Looks like it was Alastair Haig who’s left.

Stephen, he thought I was a clinician interested in buying the AIHL test. Once I explained I was a shareholder, he didn’t really want to speak with me!

What’s the evidence that he’s left? If so, then CEO leaving abruptly as well as business development manager, coupled with the chairman buying 1M shares could signify a buy out or takeover, no?

The business development manager is Patrick Breen. I had questions about potential AIHL sales in the past and he did respond to my email and we had a telephone conversation. He came over from omega diagnostic - perhaps not a great accolade.

Thanks hangs2left and Lionel for your posts. It shows that the company is doing things behind the scenes. I’m hoping that coupled with the chairman’s buy bodes well for the future.

Lospeculatore, I imagine institutions were put off by the precarious funding situation we were in. However, with that out of the way and the very recent full NICE recommendation, and now NHS orders, I’d hope we’ll be looked at more seriously now.

I believe the AIHL being put the new route which paradoxically slowed down implementation despite a conditional recommendation really affected sentiment here. That was completely unexpected by investors, the company and even the NHS. But it was a new regime and everyone’s now wiser.

FDA approval for will be quick with the new designation and that’ll be a game changer for AIHL.

With CYP2C19, I think we’ll get uptake incrementally by other stroke centres and trusts in the days ahead.

So, I think institutions will be looking at us now.

The company needs institutional investors. Relying on day traders and impatient retail investors results in precisely what we’ve had with the SP this morning.

I had always thought it’d make sense for Astra Zeneca to buy because they make the alternative to clopidogrel. Brilique costs £54.60 a month. That’s huge profits for them for every patient swapped.

Ask is 3.45 on ii

I agree Gloria. Gino, with all the technical knowledge and now on a much larger salary should demostrate his conviction in the products that he's developed by buying in massively.

Wrt to Cheek, his pitiful buy at the placing maybe demonstrated that his hear was never really in it. We'll never know what happens behind the scenes but the optics is not good.

This one isn’t a case of having to convince an NHS manager because the cost of the test will not come out of the local Trust budget (as per AIHL) but is paid for centrally by NHS England.

I don’t believe it works like that in this case Gloria. Whichever test it ordered NHS England will pay for - don’t forget not testing is more expensive than any test.

I agree with you Roger. But sales contracts can’t the too far away now. Unlike AIHL this one’s paid for by NHS England. I’m confident Manchester will announce soon, and we know already North Thames are doing workshops in end of September.

From memory, I’m in a similar situation to you Roger. I’d also reluctantly stay for the long haul if required. However, even in worst case scenario tomorrow, ie. No approval for POC, there may be other sources of funding for the test; Cheek mentioned it in the presentation.

Also, there’s AIHL approval by FDA which promises to be another game changer. The future’s bright I think whatever happens tomorrow.

From NICE website:

Final draft guidance

Final draft guidance describes the committee's final recommendations. This may be after consultation on draft guidance, or a topic may go straight to final draft guidance.

It is sent to consultees so that they can appeal, or point out if there has been a process or factual error, before publication.

Since the company hasn’t stated it has been consulted for appeal, can we assume the test has full recommendation? In any case, the market doesn’t seem too impressed at present.

Thanks to both of onlyprofit and EmeraldCarrots, very interesting and exciting. I did a very small amount of trading during Covid period. I did reasonably well (although that was obviously an unique time.

Hi emerald carrots, yes I got that impression that you were a trader.

How much initial capital would one need to make a living from it? What sort of percentages do you typically make, if you don’t mind me asking?

As an indicator for future potential of POC tests, this a old but good news article:

https://www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not-work-on-most-patients-5508670.html

It has been stated by detractors of the company that since its inception the company has wasted years and millions. However, another way to see it is that any other company to get to the stage were at now will need to invest the same sums and time. GDR have a clear head start in this field.

Yes big hammer, other possible uses of essentially the exact same test with small modifications include antidepressants and painkillers including codeine. Just google which drugs use the Cytochrome P450 pathway.

Again, the reason the company focused on these two tests initially is the time critical nature.

Sebo, you’re correct about the time issue. There’s a reason the company focused on AIHL and clopidpgrel first, because these tests are time critical.

In the consultation, time and again it was highlighted that the lab tests could not meet the time requirement. The NICE response was repeatedly that POC could be used.

Given that it is NICEs own commendation that antiplatelet therapy be initiated within 24hours, it would be paradoxical to rule out POC when the reality is a remote lab tests simply can’t do it in the time frame. I think Roger’s thinking that POC would definitely be allocated the more serious 35,000 tests seems an intelligent approach.

NICE must consider cost and efficacy. The consultation could not definitely find that labs were cheaper. The only distinct advantage was the speculative ability to do additional tests at the same time in a lab.

If POC is somehow ruled out it the final recommendation, the confidence clinicians have in NICE would be diminished.